885276-09-5 Usage
Uses
Used in Pharmaceutical Synthesis:
6-Bromo-imidazo[1,2-a]pyridine-2-carboxaldehyde is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity allow for the creation of diverse molecules with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 6-Bromo-imidazo[1,2-a]pyridine-2-carboxaldehyde serves as a building block for the development of new agrochemicals, such as pesticides and herbicides, due to its ability to form a wide range of chemical structures.
Used in Organic Synthesis:
6-Bromo-imidazo[1,2-a]pyridine-2-carboxaldehyde is utilized as a versatile intermediate in organic synthesis, enabling the formation of various complex organic compounds with potential applications in different fields.
Used in Medicinal Chemistry:
In medicinal chemistry, 6-Bromo-imidazo[1,2-a]pyridine-2-carboxaldehyde is employed as a starting material for the development of new drugs and drug candidates, thanks to its unique structure and reactivity.
Used in Material Science:
6-Bromo-imidazo[1,2-a]pyridine-2-carboxaldehyde has potential applications in material science, where its unique structure and properties can be exploited to develop new materials with specific characteristics and functions.
Check Digit Verification of cas no
The CAS Registry Mumber 885276-09-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 6 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 885276-09:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*6)+(2*0)+(1*9)=215
215 % 10 = 5
So 885276-09-5 is a valid CAS Registry Number.
885276-09-5Relevant articles and documents
HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
-
Paragraph 0360; 0362, (2020/07/16)
The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
Diversity-Oriented Synthesis of β-Lactams and γ-Lactams by Post-Ugi Nucleophilic Cyclization: Lewis Acids as Regioselective Switch
Li, Zhenghua,Sharma, Upendra Kumar,Liu, Zhen,Sharma, Nandini,Harvey, Jeremy N.,Van Der Eycken, Erik V.
supporting information, p. 3957 - 3962 (2015/06/30)
Heterocyclic fused α-methylene β-lactams were successfully synthesized by a post-Ugi InIII-catalyzed intramolecular addition reaction. Switching from InCl3 to AlCl3 led to the regioselective synthesis of α,β-unsaturated γ-lactams. Moreover, replacing terminal alkynes by substituted alkynes in the Ugi adducts resulted in the exclusive formation of γ-lactams with both catalytic systems. A regioselective approach for the synthesis of heterocyclic fused α-methylene β-lactams and α,β-unsaturated γ-lactams by employing a Ugi reaction followed by InIII- or AlIII-catalyzed intramolecular nucleophilic addition is reported.
